The
in vitroactivities of 8 newly cephem compounds, cefoxitin (CFX), cefmetazole (CMZ), latamoxef (LMOX), cefotaxime (CTX), ceftizoxime (CZX), cefmenoxime (CMX), cefotiam (CTM) and cefoperazone (CPZ), against
Klebsiella spp. and
Bacteroides fragilis and the therapeutic effects of them against experimental mixed infections due to
K. oxytoca and
B. fragilis were studied, and the following results were obtained.
1.
B. fragilis GAI-588 was inoculated in the abdominal cavity of a mouse to which
K. oxytoca 230-1 was preinfected. And then 100% of a death rate, although was 0% in single infection by
K. oxytoca or
B. fragilis, was recognized in the mixed infection.
2. The
in vitro antibacterial activity against
Klebsiella spp.(54 strains) was excellent in the order of CZX>CTX>CMX>LMOX>CTM>CMZ>CFX>CPZ. Against
B. fragilis (73 strains), cephamycins, CFX, CMZ and LMOX were superior to other cephalosporins tested: namely, the activity was in the order of LMOX>CFX=CMZ>CZX>CTX>CMX>CPZ>CTM.
3. The therapeutic effects of cephamycins, LMOX, CFX and CMZ, which showed resistance to hydrolysis byβ-lactamases of both
K. oxytoca and
B. fragilis, against experimental mixed infections due to
K. oxytoca and
B. fragilis were superior to oxime-cephalosporins, CTX, CZX and CMX, which showed resistance only to theβ-lactamase of
K. oxytoca. CTM and CPZ, which did not show resistance to theβ-lactamases, were inferior.
View full abstract